Trial Profile
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms URBAN
- Sponsors ViiV Healthcare
- 11 Oct 2023 Planned End Date changed from 25 Aug 2023 to 19 Feb 2024.
- 11 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 09 Feb 2023 Planned End Date changed from 14 Apr 2023 to 25 Aug 2023.